JTJulianna J. Tomlinson

Julianna J. Tomlinson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julianna J. Tomlinson has a total of 226 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ASC specks and α-synuclein amplify microglial NLRP3 inflammasome activation and co-localize with Lewy body pathology

    by Karan Thakur, Christine Péladeau, Melissa Hewitt, Klaudia Baumann, David Cai, John M. Woulfe, Julianna J. Tomlinson, Michael G. Schlossmacher, Jagdeep K. Sandhu

    Neuroinflammation is a hallmark of several chronic neurodegenerative disorders, including Parkinson’s disease (PD) and other synucleinopathies, and is closely associated with microglial activation. The inflammasome adaptor protein apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) undergoes oligomerization upon inflammasome activation, resulting in the formation of ASC specks. These structures are recognized by microglia as damage-associated molecular patterns (DAMPs), thereby promoting inflammatory signaling. Recent studies have demonstrated that extracellular ASC specks associate with amyloid-β (Aβ), and that uptake of ASC-Aβ composites by microglia amplifies pro-inflammatory responses. Although ASC specks have also been shown to potentiate α-synuclein (αSyn) preformed fibril-induced pathology, their interaction with monomeric αSyn and their effects on inflammasome activation remain poorly understood. Here, we co-stimulated murine SIM-A9 microglia with ASC-αSyn assemblies and evaluated their effects on NLRP3 inflammasome activation. Electron microscopy revealed a close association between ASC fibrils and αSyn monomers. Exposure of microglia to ASC-αSyn enhanced NLRP3 inflammasome activation, as evidenced by increased ASC speck formation, caspase-1 activation, and secretion of IL-1β and IL-18, when compared to ASC or αSyn alone. In addition, immunohistochemical analyses of post mortem brain tissue from patients with dementia with Lewy bodies demonstrated ASC expression in regions exhibiting αSyn pathology and showed ASC co-localization with αSyn within Lewy bodies. Collectively, these findings identify ASC-αSyn assemblies as potent amplifiers of NLRP3 inflammasome signaling and suggest a mechanism through which they may contribute to sustained neuroinflammation in synucleinopathies.

  • Open Access

    PD-RISK Index: Piloting an unsupervised toolkit to identify adults with Parkinson disease

    by Juan Li, Kelsey Grimes, Joseph Saade, David Lewis, Julianna J. Tomlinson, Andrew Frank, Tim Ramsay, Natalina Salmaso, Douglas Manuel, Michael G. Schlossmacher

    Effective screening for Parkinson disease (PD) is important for symptom management and patient recruitment into disease-modifying trials. Here, we examined the performance of the PD-RISK Index toolkit in identifying PD patients at home without supervision. Between 2022-2024, we recruited 305 participants (ages, 40–85 years): 93 with typical PD; 66 had other neurological conditions; and 146 were healthy controls. Two versions of the toolkit were completed: An original, 69-item-long questionnaire with the 40-scent University-of-Pennsylvania-Smell-Identification-Test (UPSIT); thereafter, a simplified, 11-item-short questionnaire with a newly-developed 8-scent smell test and responses submitted online. The corresponding summary scores (‘PD-RISK Indices’) were calculated for each subject to evaluate diagnostic performances. In both versions, PD patients had higher questionnaire scores and worse olfaction than healthy controls ( P ), as expected; scores for subjects with other neurological conditions ranked at intermediate levels. The simplified 11-item questionnaire outperformed the original version in identifying PD. The abbreviated 8-scent smell test and the UPSIT booklet performed equally well in detecting hyposmia. The simplified PD-RISK Index showed the highest diagnostic performance in identifying PD patients amongst all participants; at a value of 23 (range, 0–100, where higher scores indicate higher PD risk), we measured a sensitivity of 0.98, specificity of 0.83, and positive and negative likelihood ratios of 5.88 and 0.02, respectively. The simplified ‘PD-RISK Index’ showed stable performance across sexes and disease duration. Our study reveals that unsupervised screening for manifest PD can be effectively carried out at home using an 11-item questionnaire, 8-scent smell test and online data entry. The plain language title: The PD-RISK Index study: Facilitating an earlier diagnosis of adults with Parkinson disease by screening at home with a short questionnaire and a simplified smell test Plain language summaries: Effective screening for Parkinson disease (PD) is important for symptom management by healthcare workers and the recruitment of patients into disease modifying trials. We previously published a two-step model for this purpose, which has been validated using several established study cohorts. The study below represents a field-test of this model and the toolkit to implement it (i.e. a self-report questionnaire and a smell test) using a real-world setting. Between 2022-2024, 305 participants (ages, 40-85 years) were recruited into the study: 93 with typical PD; 66 had other neurological conditions; 146 were healthy. Two versions of the toolkit were completed at-home without supervision by a healthcare worker: (1) an original , 69-item-long questionnaire and a 40-scent smell test; (2) a simplified , 11-item-short questionnaire with a newly created, 8-scent smell test. Accordingly, two versions of summary scores (‘PD-RISK Index’) were calculated for each subject to examine group classification. Several performance metrics were used to evaluate diagnostic performances and to suggest clinically relevant thresholds. In both versions, PD patients had significantly higher questionnaire scores (meaning higher risk of having PD) and lower smell test scores (meaning more impaired sense of smell) than healthy controls; scores for subjects with other neurological conditions ranked at intermediate levels. The simplified questionnaire outperformed the original version in diagnostic accuracy. The abbreviated smell test performed as well as the 40-item version in identifying hyposmia. The simplified ‘PD-RISK Index’ showed stable performance across sexes and disease duration. This study shows that non-invasive and unsupervised screening for manifest PD can be effectively carried out remotely using a simple 11-item questionnaire, an abbreviated 8-scent smell test and an online data entry system, thereby generating a PD-RISK Index for each individual.

  • Open Access

    Elevated brain α-synuclein, phosphorylated-tau, and oxidative stress in mice that survived influenza A pneumonitis

    by Michaela O. Lunn, Karan Thakur, Nathalie A. Lengacher, Quinton Hake-Volling, Julianna J. Tomlinson, Subash Sad, Earl G. Brown, Michael G. Schlossmacher

    Influenza virus infection increases the incidence of parkinsonism in humans. We have previously shown that allelic variants at the Parkinson’s disease (PD)-linked Lrrk2 locus modulate host responses in vivo . Here, we asked whether Lrrk2 kinase activity alters disease outcomes in adult mice that survived a nasally acquired infection. We inoculated mice with the mouse adapted A/Fort Monmouth/1/1947 influenza A virus, serotype H1N1 (LD 50 , 2×10 3 plaque forming units), leading to pneumonitis. We found that neither the hyperkinase-active Lrrk2 p.G2019S knock-in mutant nor the kinase-dead Lrrk2 p.D1994S mutant altered the course of an acute H1N1 lung infection. We then probed for long-term effects of H1N1 pneumonitis on brain health by monitoring surviving mice for six weeks post-inoculation. Intriguingly, at this time point, when mice had recovered and showed no detectable viral proteins in the brain, levels of H 2 O 2 and protein nitrotyrosination were significantly elevated in H1N1 survivors vs. mock-treated littermates. In addition, total α-synuclein concentrations were increased in an infection-dependent manner but independent of the Lrrk2 genotype. Intriguingly, at the same timepoint, the ratio of phosphorylated-to-total tau (but not total tau itself) was significantly increased in the brains of H1N1-virus exposed Lrrk2 p.G2019S mice compared to wild-type animals. Our collective results demonstrate that a preceding pneumotropic influenza A virus infection can lead to a rise in several neurodegeneration-linked markers in the brains of surviving mice. The increased ratio of phosphorylated-to-total tau in Lrrk2 p.G2019S animals adds to the growing evidence of interactions between specific microbial pathogens and allelic variants at the Lrrk2 locus. The described outcomes in animals that survived an influenza A virus infection may be of relevance to the incidence of neurodegenerative diseases in ageing humans.


  • Open Access

    Variants in Lrrk2 and Snca deficiency do not alter the course of primary encephalitis due to neurotropic reovirus T3D in newborn mice

    by Michaela O. Lunn, Christopher Rousso, Julianna J. Tomlinson, Earl G. Brown, Michael G. Schlossmacher

    Variants at the leucine-rich repeat kinase-2 (LRRK2) and α-synuclein (SNCA) loci are associated with Parkinson’s disease (PD) risk. Viral infections have also been linked to increased risk of developing PD. In exploring a role for each of the encoded proteins in host response against brain-directed viral infections, we previously demonstrated that two Lrrk2 knock-in variants as well as Snca expression altered survival rates from viral encephalitis following intranasal inoculation of newborn mice with a double-stranded RNA virus: respiratory-enteric-orphan virus, serotype-3 strain Dearing (reovirus T3D). Here, we examined whether outcomes of direct inoculation of the brain by reovirus T3D, which invariably causes lethal encephalitis within 15 days, would also be modified by variants in Lrrk2 and Snca. When we inoculated newborn mice intracerebrally with reovirus T3D, we found that compared to wild-type littermates Lrrk2 p.G2019S kinase-hyperactive and p.D1994S kinase-inactive mutant mice did not show any significant difference in time-to-death or in viral titres in the brain, and revealed no sex difference. In parallel studies, the reduction or absence of endogenous α-synuclein did not alter the course of disease in reovirus T3D-infected mice. Together, these findings suggest that while variants in the PD-linked Lrrk2 and Snca genes influenced disease outcomes of intranasally acquired reovirus T3D encephalitis, they did not affect survival outcomes in the intracerebrally acquired reovirus T3D encephalitis model.

  • Open Access

    Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory

    by Juan Li, Kelsey Grimes, Joseph Saade, Julianna J. Tomlinson, Tiago A. Mestre, Sebastian Schade, Sandrina Weber, Mohammed Dakna, Tamara Wicke, Elisabeth Lang, et al.

    To develop a simplified smell test for identifying patients with Parkinson’s disease (PD), we reevaluated the Sniffin’-Sticks-Identification-Test (SST-ID) and University-of-Pennsylvania-Smell-Identification-Test (UPSIT), using three case-control studies. These included 301 patients with PD or dementia with Lewy bodies (DLB), 68 subjects with multiple-system atrophy (MSA) or progressive supranuclear palsy (PSP), and 281 healthy controls (HC). Scents were ranked by area-under-the-curve values for group classification and results leveraged by 8 published studies with 5853 individuals. PD/DLB patients showed markedly worse olfaction than controls, whereas scores for MSA/PSP subjects were intermediate. We identified and validated a subset of 7 shared odorants that performed similarly to the traditional 16-scent SST-ID and 40-scent UPSIT tests in distinguishing PD/DLB from HC. There, the identification of 4 or fewer scents out of 7 served as an effective cut-off between the two groups. We also identified a critical role for distractors (from correct answers) and age on olfaction performance.


  • Open Access

    A Protocol for Neuralized Murine Olfactory Organoids

    by Alp Ozgun, Priya Suman, Josée Coulombe, aSCENT-PD Investigators, Earl G. Brown, Julianna J. Tomlinson, John M. Woulfe, Michael G. Schlossmacher

    Chronic olfactory dysfunction can be associated with parkinsonism, dementia, demyelinating disorders and schizophrenia. The olfactory epithelium (OE) represents an interface between the environment and the central nervous system. Mounting evidence implicates environmental factors in neurodegenerative disease processes, necessitating investigations into their interactions with the host’s genome. In Parkinson disease, hyposmia often precedes motor symptoms, raising the possibility that the OE could be involved in disease initiation. We previously demonstrated abundant α-synuclein expression in mammalian OE as well as aggregate formation in the olfactory nerve. Current in vitro models of OE are limited, relying primarily on post-mitotic cultures established from biopsies. To address this gap, we present a method for generating olfactory organoids of OE from adult mice. These organoids comprise neuronal and non-neuronal cell types, including sustentacular cells, thus encompassing structural elements of OE in situ . Expression of the olfactory sensory neuron marker OMP and Parkinson’s-linked α-synuclein was also detected in olfactory organoids, highlighting their potential usefulness to mechanistic research. We established OE organoids that were kept in culture for up to 3 weeks. In addition, we inoculated organoids with the neurotropic vesicular stomatitis virus to model infections. We conclude that this olfactory organoid model system offers a new platform for studying airborne environmental factors in their interactions with a genetically defined host; this, to study OE biology and enable the exploration of disease processes within olfactory tissue.


  • Open Access

    Variants in Lrrk2 and Snca deficiency do not alter the course of primary encephalitis due to neurotropic reovirus T3D in newborn mice

    by Michaela O. Lunn, Christopher Rousso, Julianna J. Tomlinson, Earl G. Brown, Michael G. Schlossmacher

    Variants of the leucine-rich repeat kinase-2 ( LRRK2 ) and α-synuclein ( SNCA ) genes are associated with Parkinson’s disease risk. We previously demonstrated that two Lrrk2 knock-in variants as well as Snca expression alter survival rates from combined pneumonitis and encephalitis following intranasal inoculation of newborn mice with a double-stranded RNA virus: respiratory-enteric-orphan virus, serotype-3 strain Dearing (reovirus T3D). Here, we examined whether outcomes of direct inoculation of the brain by reovirus T3D, which invariably causes lethal encephalitis within 15 days, would also be modified by variants in Lrrk2 and Snca . When we inoculated newborn mice intracerebrally with 5×10 2 plaque-forming units of reovirus T3D, we found that, when compared to wild-type littermates, Lrrk2 p.G2019S mutant mice and kinase-dead p.D1994S mutant animals showed the same time-to-death intervals post-infection, revealed no sex difference, and had similar viral titres in the brain. Furthermore, the reduction or absence of endogenous α-synuclein also did not alter the course of encephalitis in parallel studies. These outcomes are in contrast to those following the intranasal inoculation paradigm of newborn mice, in which Lrrk2 and wild-type α-synuclein were both protective in infection outcomes. Together, these findings suggest that the Parkinson’s disease-linked Lrrk2 and Snca genes contribute predominantly to systemic, innate responses by the host following reovirus T3D exposure.

  • Open Access

    Correction: Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19

    by Nathalie A. Lengacher, Julianna J. Tomlinson, Ann‑Kristin Jochum, Jonas Franz, Omar Hasan Ali, Lukas Flatz, Wolfram Jochum, Josef Penninger, aSCENT-PD Investigators, Christine Stadelmann, et al.


  • Open Access

    Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation

    by Juan Li, Kelsey Grimes, Joseph Saade, Julianna J. Tomlinson, Tiago A. Mestre, Sebastian Schade, Sandrina Weber, Mohammed Dakna, Tamara Wicke, Elisabeth Lang, et al.

    Background: Reduced olfaction is a common feature of patients with typical Parkinson disease (PD). We sought to develop and validate a simplified smell test as a screening tool to help identify PD patients and explore its differentiation from other forms of parkinsonism. Methods: We used the Sniffin’ Sticks Identification Test (SST-ID) and the University of Pennsylvania Smell Identification Test (UPSIT), together with data from three case-control studies, to compare olfaction in 301 patients with PD or dementia with Lewy bodies (DLB) to 36 subjects with multiple system atrophy (MSA), 32 individuals with progressive supranuclear palsy (PSP) and 281 neurologically healthy controls. Individual SST-ID and UPSIT scents were ranked by area under the receiver operating characteristic curve (AUC) values for group classification, with 10-fold cross-validation. Additional rankings were generated by leveraging results from eight published studies, collectively including 5,853 unique participants. Lead combinations were further validated using (semi-)independent datasets. An abbreviated list of scents was generated based on those shared by SST-ID and UPSIT. Findings: We made the following five observations: (i) PD and DLB patients generally had worse olfaction than healthy controls, as published, with scores for MSA and PSP patients ranking as intermediate. (ii) SST-ID and UPSIT scents showed distinct discriminative performances, with the top odorants (licorice, banana, clove, rose, mint, pineapple and cinnamon) confirmed by external evidence. (iii) A subset of only seven scents demonstrated a similar performance to that of the complete 16-scent SST-ID and 40-scent UPSIT kits, in both discovery and validation steps. Seven scents distinguished PD/DLB subjects from healthy controls with an AUC of 0.87 (95%CI 0.85-0.9) and PD/DLB from PSP/MSA patients with an AUC of 0.73 (95%CI 0.65-0.8) within the three cohorts (n=650). (iv) Increased age was associated with a decline in olfaction. (v) Males generally scored lower than females, although this finding was not significant across all cohorts. Interpretation: Screening of subjects for typical Parkinson’s-associated hyposmia can be carried out with a simplified scent identification test that relies on as few as seven specific odorants. There, the discrimination of PD/DLB subjects vs. age-matched controls is more accurate than that of PD/DLB vs. PSP/MSA patients. Funding: This work was supported by: Parkinson Research Consortium; uOttawa Brain & Mind Research Institute; and the Aligning Science Across Parkinson’s Collaborative Research Network. Research in context: Evidence before this study: Chronic hyposmia is a common feature of Parkinson disease (PD) and dementia with Lewy bodies (DLB), which often precedes motor impairment and cognitive dysfunction by several years; it is also frequently associated with α-synuclein aggregate formation in the bulb. The presence of hyposmia increases an individual’s likelihood of having -what has recently been proposed as- a neuronal synucleinopathy disease, by >24-fold. Despite the strong association of PD with reduced olfaction, little is understood about it clinically, such as whether it is affected by sex and age, and whether hyposmia of PD is associated with the same scent identification difficulty seen in other conditions that present with parkinsonism. Moreover, due to its time-consuming nature and traditional administration by healthcare workers, extensive olfactory testing is not routinely performed during neurological assessments in movement disorder clinics. Added value of this study: We analyzed the performance of both the Sniffin’ Sticks Test kit and UPSIT battery to discriminate between healthy controls, patients with PD/DLB and those with MSA or PSP. Comparison to and juxtaposition with eight other published studies allowed for the generation of a markedly abbreviated smell identification test that unified both tests, as described. Group classification performance by each scent and its distractors was further analyzed using machine learning and advanced Item Response Theory methods. Relations between each scent tested, sex and age were analyzed for the first time. Our findings suggest concrete steps to be implemented that would allow for simplified, routine olfaction testing in the future. Implications of all the available evidence: Olfaction testing has emerged as an important neurological assessment part when examining subjects with Parkinson’s and those at risk of it. A simple, validated smell test containing fewer scents than current options could facilitate rapid testing of olfaction in clinic settings and at home, without supervision by healthcare workers. The usefulness of such a non-invasive test in population health screening efforts could be further enhanced when coupled to a self-administered survey that includes questions related to other risk factors associated with PD. As such, large-scale community screening and applications to routine practice in family doctors’ offices as well as in specialty clinics could be made operationally feasible and cost-effective.


  • Open Access

    Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19

    by Nathalie A. Lengacher, Julianna J. Tomlinson, Ann-Kristin Jochum, Jonas Franz, Omar Hasan Ali, Lukas Flatz, Wolfram Jochum, Josef Penninger, aSCENT-PD Investigators, Benjamin Arenkiel, et al.

    The majority of patients with Parkinson disease (PD) experience a loss in their sense of smell and accumulate insoluble α-synuclein aggregates in their olfactory bulbs (OB). Subjects affected by a SARS-CoV-2-linked illness (COVID-19) also frequently experience hyposmia. We previously postulated that microglial activation as well as α-synuclein and tau misprocessing can occur during host responses following microbial encounters. Using semiquantitative measurements of immunohistochemical signals, we examined OB and olfactory tract specimens collected serially at autopsies between 2020 and 2023. Deceased subjects comprised 50 adults, which included COVID19 + patients (n = 22), individuals with Lewy body disease (e.g., PD; dementia with Lewy bodies (n = 6)), Alzheimer disease (AD; n = 3), and other neurodegenerative disorders (e.g., progressive supranuclear palsy (n = 2); multisystem atrophy (n = 1)). Further, we included neurologically healthy controls (n = 9), and added subjects with an inflammation-rich brain disorder as neurological controls (NCO; n = 7). When probing for microglial and histiocytic reactivity in the anterior olfactory nuclei (AON) by anti-CD68 immunostaining, scores were consistently elevated in NCO and AD cases. In contrast, microglial signals on average were not significantly altered in COVID19 + patients relative to healthy controls, although anti-CD68 reactivity in their OB and tracts declined with progression in age. Mild-to-moderate increases in phospho-α-synuclein and phospho-tau signals were detected in the AON of tauopathy- and synucleinopathy-afflicted brains, respectively, consistent with mixed pathology, as described by others. Lastly, when both sides were available for comparison in our case series, we saw no asymmetry in the degree of pathology of the left versus right OB and tracts. We concluded from our autopsy series that after a fatal course of COVID-19, microscopic changes in the rostral, intracranial portion of the olfactory circuitry -when present- reflected neurodegenerative processes seen elsewhere in the brain. In general, microglial reactivity correlated best with the degree of Alzheimer’s-linked tauopathy and declined with progression of age in COVID19 + patients.